BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...Inspiration’s Chapter 11 auction process. In 2013, IB1001 and two preclinical programs were sold to Cangene Corp....
BioCentury | Apr 7, 2017
Company News

Emergent BioSolutions, HHS infectious news

...years. Emergent did not respond to inquiries. Emergent gained BAT through its 2014 acquisition of Cangene Corp....
BioCentury | Mar 30, 2015
Clinical News

Anthrasil anthrax immune globulin IV regulatory update

...Drug status for the indication. Emergent gained rights to the product through its acquisition of Cangene Corp....
BioCentury | Mar 26, 2015
Company News

Emergent's anthrax treatment gets FDA nod

...Orphan Drug status from FDA. Emergent gained rights to the product through its acquisition of Cangene Corp....
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...a vaccine to induce broadly neutralizing antibodies against HIV 2014 Viral Hemorrhagic Fever Immunotherapeutic Consortium Cangene Corp....
BioCentury | Aug 18, 2014
Company News

Emergent BioSolutions, U.S. Centers for Disease Control and Prevention infectious news

...the total contract value to $36.6 million. Emergent gained VIGIV through its February acquisition of Cangene Corp....
BioCentury | Aug 11, 2014
Clinical News

Anthrax immune globulin IV regulatory update

...a solution of human polyclonal antibodies that target anthrax toxins - through its acquisition of Cangene Corp....
BioCentury | Aug 8, 2014
Company News

Emergent submits BLA for anthrax treatment

...a solution of human polyclonal antibodies that target anthrax toxins -- through its acquisition of Cangene Corp....
BioCentury | Mar 31, 2014
Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

...performing industrial-level expression of antibodies, Zalgen is helping to generate antibodies against the arenaviruses, and Cangene Corp....
BioCentury | Mar 3, 2014
Company News

Cangene, Emergent BioSolutions deal

...Biodefense company Emergent completed the acquisition of Cangene for $3.24 per share in cash or $222...
...$3.24 per share in cash or $222 million in cash (see BioCentury, Dec. 16, 2013). Cangene Corp....
Items per page:
1 - 10 of 211
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...Inspiration’s Chapter 11 auction process. In 2013, IB1001 and two preclinical programs were sold to Cangene Corp....
BioCentury | Apr 7, 2017
Company News

Emergent BioSolutions, HHS infectious news

...years. Emergent did not respond to inquiries. Emergent gained BAT through its 2014 acquisition of Cangene Corp....
BioCentury | Mar 30, 2015
Clinical News

Anthrasil anthrax immune globulin IV regulatory update

...Drug status for the indication. Emergent gained rights to the product through its acquisition of Cangene Corp....
BioCentury | Mar 26, 2015
Company News

Emergent's anthrax treatment gets FDA nod

...Orphan Drug status from FDA. Emergent gained rights to the product through its acquisition of Cangene Corp....
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...a vaccine to induce broadly neutralizing antibodies against HIV 2014 Viral Hemorrhagic Fever Immunotherapeutic Consortium Cangene Corp....
BioCentury | Aug 18, 2014
Company News

Emergent BioSolutions, U.S. Centers for Disease Control and Prevention infectious news

...the total contract value to $36.6 million. Emergent gained VIGIV through its February acquisition of Cangene Corp....
BioCentury | Aug 11, 2014
Clinical News

Anthrax immune globulin IV regulatory update

...a solution of human polyclonal antibodies that target anthrax toxins - through its acquisition of Cangene Corp....
BioCentury | Aug 8, 2014
Company News

Emergent submits BLA for anthrax treatment

...a solution of human polyclonal antibodies that target anthrax toxins -- through its acquisition of Cangene Corp....
BioCentury | Mar 31, 2014
Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

...performing industrial-level expression of antibodies, Zalgen is helping to generate antibodies against the arenaviruses, and Cangene Corp....
BioCentury | Mar 3, 2014
Company News

Cangene, Emergent BioSolutions deal

...Biodefense company Emergent completed the acquisition of Cangene for $3.24 per share in cash or $222...
...$3.24 per share in cash or $222 million in cash (see BioCentury, Dec. 16, 2013). Cangene Corp....
Items per page:
1 - 10 of 211